TRxADE HEALTH(US:MEDS)2026-03-30 12:05Acquisition and Strategic Realignment - On July 25, 2024, the company acquired Scienture LLC, a specialty pharmaceutical company focused on cardiovascular and central nervous system diseases, which launched its first product for hypertension and is developing a second product for opioid overdose [406]. - The company completed the acquisition of Superlatus on July 31, 2023, with shareholders receiving an aggregate value of $225,000,169 at the time of closing [413]. - The company divested several subsidiaries, including Community Specialty Pharmacy and Alliance Pharma Solutions, as part of a strategic realignment to focus on core operations and enhance long-term value [422]. Financial Performance - Revenues for the year ended December 31, 2025, were $431,609, an increase of $294,966 or approximately 216% compared to $136,643 in 2024, driven by initial sales of ARBLI™ [435]. - Gross profit for 2025 was $331,482, resulting in a gross margin of 76.8%, compared to a gross profit of $6,005 and a gross margin of 4.4% in 2024 [435]. - Total operating expenses for 2025 were $42,922,324, an increase of $28,215,304 from $14,707,020 in 2024, primarily due to non-cash impairment charges of $26,346,050 [436]. - Net loss from continuing operations, net of tax, was $41,512,264 for 2025, compared to a net loss of $15,803,908 in 2024, largely due to the impairment charges [438]. - The net loss for 2025 was $(41,512,264), compared to a net income of $9,065,798 in 2024, indicating a substantial decline in profitability [449]. Cash Flow and Financing - As of December 31, 2025, the company had cash and cash equivalents of $6,662,008 and positive working capital of approximately $5,181,000, an improvement of approximately $6,782,000 from a working capital deficit of $(1,601,416) as of December 31, 2024 [427]. - The company raised approximately $26.3 million in gross equity proceeds through equity line of credit and other transactions during the year ended December 31, 2025 [424]. - The company reported net cash provided by financing activities from continuing operations of $19,733,595 for the year ended December 31, 2025, compared to net cash used of approximately $12,980,000 for the year ended December 31, 2024 [432]. - The company anticipates that its existing cash, combined with growing revenues from product commercialization, will be sufficient to fund operations for at least the next twelve months [428]. Operating Activities and Expenses - Net cash used in operating activities from continuing operations for the year ended December 31, 2025 was $13,382,482, compared to $13,286,163 for the year ended December 31, 2024, with a net loss of $43,507,142 being the primary driver [430]. - Wage and salary expenses remained relatively flat at $2,118,568 in 2025 compared to $2,111,066 in 2024, while professional fees increased by 65% to $2,407,822 [436]. - Research and development expenses decreased to $1,956,270 in 2025 from $2,236,690 in 2024, reflecting shifts in spending across pipeline programs [436]. Tax and Interest - Interest income increased to $302,702 in 2025 from $135,337 in 2024, while interest expense rose significantly to $4,083,206 from $1,335,631 [437]. - The company recognized a tax benefit of $1,994,878 in 2025, reflecting changes in deferred tax liabilities due to impairment charges [437]. EBITDA and Impairment Charges - For the year ended December 31, 2025, adjusted EBITDA was $(5,384,274), a significant decrease from $17,820,898 in 2024, reflecting the transition to a focused specialty pharmaceutical company [449]. - The company recognized non-cash impairment charges of $26,346,050 in 2025, impacting the adjusted EBITDA [449]. Other Financial Information - There was no income from discontinued operations in 2025, compared to $27,310,278 in 2024, primarily from the sale of MMS assets [438]. - Depreciation and amortization expenses increased to $491,781 in 2025 from $53,361 in 2024, highlighting increased operational costs [449]. - Stock-based compensation (non-cash) increased to $6,378,981 in 2025 from $4,623,878 in 2024, indicating a rise in employee compensation costs [449]. - The company did not have any off-balance sheet arrangements during the periods presented [450]. - The company is classified as a "smaller reporting company" and is not required to provide certain market risk disclosures [452].